Comparison tool

Cartalax vs Epithalon side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

CartalaxEpithalon

Share this peptide comparison

Property	Cartalax	Epithalon
Category	Bioregulators	Bioregulators
Also known as	Ala-Glu-Asp, AED Tripeptide	Epitalon, Epithalone, AGAG
FDA approved	No	No
Clinical status	Available in Russia; not FDA approved Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	Investigational; primarily Russian research. Source notes current FDA Category 2 status pending formal reclassification activity in 2026. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Joint health, cartilage support, osteoarthritis	Longevity, telomere support, anti-aging, sleep
How it works	Cartalax is presented as AED, a short cytogen peptide for which the main proposed action is modulation of cartilage-cell gene activity. The cited source connects AED with chondrogenic markers such as SOX9, COL2 and ACAN and discusses WNT, ERK-p38 and Smad signaling in cartilage differentiation research. The evidence base described is centered on Khavinson-group and related preclinical work, so the mechanism should be treated as a research hypothesis rather than a clinically proven pathway.	Epithalon is proposed to act through telomerase-related biology, with cell-culture reports describing telomerase activity and telomere elongation in human fibroblasts. The source also notes possible effects on melatonin, antioxidant defenses, and gene expression in pineal-hypothalamic pathways. Translation from these observations to meaningful human anti-aging outcomes remains unproven in the supplied evidence.
Typical dosing	Limited community data available · See research protocols	5-10 mg daily for 10-20 days · Once daily in cycles · 10-20 days
Research dosing	10-20 mg daily · 10-30 day courses · Oral	5-10 mg daily for 10-20 days · 10-20 day cycles · Subcutaneous or intramuscular injection
Typical duration	10-30 day courses	10-20 day cycles
Administration	Oral	Subcutaneous or intramuscular injection
Timing	Morning or as directed With or without food	Before bed With or without food
Evidence level	Preclinical	Clinical Trials
Possible side effects	Generally well-tolerated (Reported by the source, but safety documentation is limited.) Mild injection site reactions (Listed as a mild reported effect.) Transient fatigue (Listed as a reported transient effect.) +2 more Mild gastrointestinal upset (Described by the source as rare.) Limited documented side-effect data (The source indicates that adverse-effect reporting is incomplete.)	Generally well-tolerated (Reported in the source, but tolerability evidence is limited by the available research base.) Injection site reactions (Reported as a possible effect with injectable administration.) Mild headache (Source describes this as transient.) +3 more Sleep disturbances (Reported as a possible effect; frequency is not established.) Risk of immunogenicity (Listed as a potential risk rather than a quantified event rate.) Long-term safety not established (The source explicitly notes uncertainty about long-term safety.)
Research summary	The supplied research summary places Cartalax in a preclinical evidence category. It cites in-vitro and animal findings, including a 2023 review that discusses AED among peptides relevant to chondrogenic differentiation and cartilage-cell signaling. Reported Russian literature describes cartilage-protective and matrix-related effects, while the source also notes limited independent Western validation and no human clinical trials. Overall, the evidence supports biological plausibility in experimental systems, not demonstrated human benefit.	The supplied research narrative gives greatest weight to laboratory and animal data. It cites a 2003 report by Khavinson and colleagues on telomerase activity and telomere changes in cultured human fibroblasts, plus a 2025 review discussing geroprotective and neuroendocrine research. Animal studies are described as reporting lifespan and tumor-incidence findings. Human evidence is characterized as limited, often small or open-label, and not independently replicated at the scale needed to prove lifespan extension or reliable telomere-length effects in people.
References	Peptibase peptides Peptibase peptides +1 more Peptibase peptides	PubMed PubMed +2 more WikipediaEpitalon Springer
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Cartalax

Epithalon

Category

Bioregulators

Also known as

Ala-Glu-Asp, AED Tripeptide

Epitalon, Epithalone, AGAG

FDA approved

Clinical status

Available in Russia; not FDA approved

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

Investigational; primarily Russian research. Source notes current FDA Category 2 status pending formal reclassification activity in 2026.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Joint health, cartilage support, osteoarthritis

Longevity, telomere support, anti-aging, sleep

How it works

Cartalax is presented as AED, a short cytogen peptide for which the main proposed action is modulation of cartilage-cell gene activity. The cited source connects AED with chondrogenic markers such as SOX9, COL2 and ACAN and discusses WNT, ERK-p38 and Smad signaling in cartilage differentiation research. The evidence base described is centered on Khavinson-group and related preclinical work, so the mechanism should be treated as a research hypothesis rather than a clinically proven pathway.

Epithalon is proposed to act through telomerase-related biology, with cell-culture reports describing telomerase activity and telomere elongation in human fibroblasts. The source also notes possible effects on melatonin, antioxidant defenses, and gene expression in pineal-hypothalamic pathways. Translation from these observations to meaningful human anti-aging outcomes remains unproven in the supplied evidence.

Typical dosing

Limited community data available · See research protocols

5-10 mg daily for 10-20 days · Once daily in cycles · 10-20 days

Research dosing

10-20 mg daily · 10-30 day courses · Oral

5-10 mg daily for 10-20 days · 10-20 day cycles · Subcutaneous or intramuscular injection

Typical duration

10-30 day courses

10-20 day cycles

Administration

Oral

Subcutaneous or intramuscular injection

Timing

Morning or as directed

With or without food

Before bed

With or without food

Evidence level

Preclinical

Clinical Trials

Possible side effects

Generally well-tolerated (Reported by the source, but safety documentation is limited.)
Mild injection site reactions (Listed as a mild reported effect.)
Transient fatigue (Listed as a reported transient effect.)

+2 more

Mild gastrointestinal upset (Described by the source as rare.)
Limited documented side-effect data (The source indicates that adverse-effect reporting is incomplete.)

Generally well-tolerated (Reported in the source, but tolerability evidence is limited by the available research base.)
Injection site reactions (Reported as a possible effect with injectable administration.)
Mild headache (Source describes this as transient.)

+3 more

Sleep disturbances (Reported as a possible effect; frequency is not established.)
Risk of immunogenicity (Listed as a potential risk rather than a quantified event rate.)
Long-term safety not established (The source explicitly notes uncertainty about long-term safety.)

Research summary

The supplied research summary places Cartalax in a preclinical evidence category. It cites in-vitro and animal findings, including a 2023 review that discusses AED among peptides relevant to chondrogenic differentiation and cartilage-cell signaling. Reported Russian literature describes cartilage-protective and matrix-related effects, while the source also notes limited independent Western validation and no human clinical trials. Overall, the evidence supports biological plausibility in experimental systems, not demonstrated human benefit.

The supplied research narrative gives greatest weight to laboratory and animal data. It cites a 2003 report by Khavinson and colleagues on telomerase activity and telomere changes in cultured human fibroblasts, plus a 2025 review discussing geroprotective and neuroendocrine research. Animal studies are described as reporting lifespan and tumor-incidence findings. Human evidence is characterized as limited, often small or open-label, and not independently replicated at the scale needed to prove lifespan extension or reliable telomere-length effects in people.

References

Peptibase peptides Peptibase peptides

+1 more

Peptibase peptides

PubMed PubMed

+2 more

WikipediaEpitalon Springer

Full profile

View Details